Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AXNX vs LIVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIVN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LIVN Overall Winner 6-Pillar Tally: AXNX 0 – 6 LIVN Matrix Metrics: AXNX 1 – 9 LIVN

As of Nov 20, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas LIVN carries 41.9/100 (SELL) at $90.73 (19.2x Forward P/E, 14.3% operating margin).

  • Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. LIVN 41.9/100 SELL), LIVN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (14.3% vs. N/A operating margin) and revenue trajectory (+9.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXNX vs LIVN
AXNX US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
LIVN NASDAQ Head-to-Head Winner
LivaNova PLC Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$90.73
-1.46% 1D
Market Cap $5.1B
TTM Revenue $1.51B
Forward P/E 19.2x
Beta / 30D Vol 0.92β · 66% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 31.0 Fund 41.0 Flow 72.0 Mom 26.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.9% over 20 days), RSI 59
RSI-14: 58.7 · SMA20: $87.76 · SMA50: $81.60

6-Pillar Scorecard Institutional Category Breakdown (AXNX 0 – 6 LIVN)

Columns: Metric · AXNX · LIVN
1. Valuation Multiples LIVN
Forward P/E N/M 19.2x
Trailing P/E N/M 26.4x
PEG Ratio N/M 0.93x
EV / Revenue N/M 3.2x
2. Growth & Scale LIVN
Revenue Growth (YoY) N/A +9.9%
Earnings Growth (YoY) N/A -78.2%
TTM Revenue (USD) N/A $1.51B
Market Cap N/A $5.1B
3. Profitability & Quality LIVN
Gross Margin N/A 67.6%
Operating Margin N/A 14.3%
Net Profit Margin N/A 13.0%
Return on Equity (ROE) N/A 15.5%
4. Balance Sheet & Cash Flow LIVN
Cash Generation (TTM) N/A $129M
Cash Flow Margin N/A 8.6%
Net Cash / Leverage N/A ROE $206M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LIVN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 37.0% (11th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat LIVN
OpEx & R&D Intensity N/A 53.3% of Rev ($803M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXNX (1) vs LIVN (9)
Institutional Metric AXNX LIVN Criterion Row Edge
Market Capitalization
Scale
N/A $5.1B Larger Scale LIVN
Trailing P/E Ratio
Valuation
N/M 26.4x Lower Multiple LIVN
Forward P/E Ratio
Valuation
N/M 19.2x Lower Multiple LIVN
Revenue Growth (YoY)
Growth
N/A +9.9% Higher Growth LIVN
Operating Margin (TTM)
Profitability
N/A 14.3% Higher Margin LIVN
Net Profit Margin
Profitability
N/A 13.0% Higher Margin LIVN
Return on Equity (ROE)
Capital Efficiency
N/A 15.5% Higher ROE LIVN
52-Week Range Position
Momentum
50% ($0–$1) 81% ($53–$99) Stronger Trend LIVN
Beta / 30D Volatility
Risk Regime
N/A 0.92β · 66% Vol Lower Realized Risk LIVN
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 41.9 / 100 (SELL) Higher Composite AXNX
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 67.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.93x PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $129M ($206M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LIVN +38.18 pp
AXNX: -26.54% · LIVN: +11.64%
3M Horizon LIVN +1.88 pp
AXNX: +16.92% · LIVN: +18.8%
6M Horizon LIVN +1.88 pp
AXNX: +16.92% · LIVN: +18.8%
1Y Horizon LIVN +1.88 pp
AXNX: +16.92% · LIVN: +18.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs LIVN. Trailing 12-month operating profitability (AXNX N/A vs LIVN 14.3%) and valuation multiples (AXNX N/M vs LIVN 19.2x Forward P/E) are benchmarked directly in Pillar 4 below.

AXNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LIVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.51B
Gross Margin67.6%
Op. Margin14.3%
ROE / Fwd P/E15.5% · 19.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AXNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVN CONSOLIDATION
98d in phase · OBV ACCUMULATION
Current IV 37.0%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LIVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LIVN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.1B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 53.3% of Rev ($803M)
90D Engineering Disclosures 0 Published

Investor FAQ AXNX vs LIVN Key Questions & Quantitative Answers

As of Nov 20, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over AXNX (AXNX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AXNX carries a Unified Composite Score of 52.1/100 (HOLD) at $0.83 (N/M Forward P/E, N/A operating margin), whereas LIVN carries 41.9/100 (SELL) at $90.73 (19.2x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While AXNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. LIVN 41.9/100 SELL), LIVN captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (14.3% vs. N/A operating margin) and revenue trajectory (+9.9% vs. N/A YoY).

LIVN leads the Growth & Scale pillar: AXNX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LIVN at +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin). On trailing 12-month operating scale, AXNX generates N/A in USD-normalized revenue versus $1.51B for LIVN. In operating R&D and SG&A reinvestment, AXNX deploys N/A (0 90-day corporate R&D disclosures) versus 53.3% of Rev ($803M) (0 disclosures) for LIVN.

LIVN screens cheaper on headline valuation multiples. AXNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LIVN trades at 19.2x Forward P/E, 26.4x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXNX (N/A ROE) versus LIVN (15.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AXNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, LIVN carries 37.0% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.